-
Jimin Trusted New Coronary Neutralizing Antibody JMB2002 is Preliminary Effective against Omicron
Time of Update: 2022-01-26
The joint team of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Jimin Trust successfully analyzed the structure of the spike protein of Omicron variant strain and the specific therapeutic antibody JMB2002.
-
Stone medicine is in full swing!
Time of Update: 2022-01-26
Figure 3: Zoledronic acid has previously reviewed companies Source: Minet Consistency Evaluation Database Zoledronic acid injection has been approved by 5 companies earlier, among which Yangzijiang, Kelun, Qilu, and Chia Tai Tianqing have been reviewed, and CSPC, the leading domestic echelon, has also won this large variety .
-
Responding to change with the same - flu "magic drug" oseltamivir
Time of Update: 2022-01-26
In the research and development process of oseltamivir, computer-aided drug design methods were widely used, and neuraminidase inhibitors with high efficiency, low toxicity and strong specificity were designed according to the three-dimensional structure of the target enzyme .
-
First-in-class Pharmaceutical Design Series: Prospects for the First Batch of Anti-COVID-19 Oral Drugs to Be Marketed in 2022
Time of Update: 2022-01-26
Based on existing research and development experience, oral antiviral drugs have several significant potential advantages: (1) they are cheaper and easier to use than antibodies already approved for non-hospitalized patients; (2) resistance to resistance-causing mutations may not be too sensitive.
-
In 2021, the 2 types of improved new drugs of chemical drugs will welcome the climax of "growth rate and increase".
Time of Update: 2022-01-26
In terms of new drug & import classification, it has nearly doubled from almost the same level in 2019, and the number of acceptance numbers of domestic improved new drugs has achieved an annual growth rate of 64% .
-
The self-developed product CT041 of Keji Pharmaceutical was awarded the "Advanced Therapy of Regenerative Medicine" by the FDA
Time of Update: 2022-01-25
HK), an innovative CAR-T cell therapy company mainly focusing on the treatment of hematological malignancies and solid tumors, recently announced that its self-developed CAR-T product CT041 was approved by the US Food and Drug Administration The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of Claudin18.
-
"Inadvertently inserted" Sildenafil - the unexpected joy of side effects research
Time of Update: 2022-01-25
Members of the Pfizer research team hypothesized that if PDE5 plays an important role in the physiology of corpus cavernosum smooth muscle, it is likely that administration of sildenafil may promote erectile responses to sexual stimulation .
-
Qilu grabs microspheres, the first imitation Novartis billion-level injection, soars by 80%
Time of Update: 2022-01-25
Figure 3: Clinical progress related to octreotide acetate microspheres for injection Source: Minet China Drug Clinical Trials Publicity Library Changchun Jinsai Pharmaceutical obtained clinical approval in 2017, and Phase I clinical trials are currently underway; Livzon Group will report production in 2020, and then obtain clinical approval; Qilu completed BE in 2021, and is now applying for listing, depending on the progress Look, winning the first copy is a high probability event .
-
"Outstanding student" among FGFR3 inhibitors - LOXO-435
Time of Update: 2022-01-25
[4] 2 Preclinical data for LOXO-435 The kinase profile data in Figure 7 and subsequent data demonstrating the safety of the compound demonstrate that LOXO-435 is a potent, highly isoform-selective FGFR3 inhibitor , is potent against FGFR3 gatekeeper resistance mutations; LOXO-435 avoids dose-limiting toxicities—hyperphosphatemia, etc.
-
What are the prospects for the development of JAK inhibitor safety warnings?
Time of Update: 2022-01-24
In September 2021, the FDA required Pfizer Xeljanz, AbbVie Rinvoq and Eli Lilly Olumiant to clearly identify patients with cardiac safety and cancer risk after receiving treatment .
-
Diversified investment drives performance growth, CRO leader may usher in the harvest period
Time of Update: 2022-01-24
Future Investment Outlook The company's outlook and layout for the next ten years of China's pharmaceutical investment business in the future, Tigermed is more like a platform, investment is divided into three levels, 100% holding Hangzhou Tigermed, Tigermed as GP fund and LP fund, major shareholder Individual investment, through the combination of listed company investment in relatively stable projects + fund investment plus leverage + personal venture investment, under the condition of controllable risks, maximize investment returns .
-
The road is long and the road is coming——On the oral administration of protein and polypeptide drugs
Time of Update: 2022-01-22
The main obstacles to the development of oral delivery systems for proteins and peptides include easy enzymatic inactivation in the gastrointestinal tract, large molecular weight, high hydrophilicity, and poor transmembrane permeability .
-
Zhenhe Technology assisted the publication of national multi-center research results led by Professor Zhou Caicun's team
Time of Update: 2022-01-22
Studies have shown that, compared with chemotherapy, camrelizumab combined with chemotherapy as a first-line treatment for patients with advanced squamous cell carcinoma of the lung can significantly improve the PFS and OS of patients .
-
How does the biomedical industrial park develop?
Time of Update: 2022-01-22
This issue of "Analysis of Development Models of Foreign Biomedical Parks" focuses on the analysis of the development models of biomedical parks in the United States, the United Kingdom, France, Japa
-
Innovate Group will announce the progress of two TST001 clinical trials at ASCO GI and IGCC International Gastric Cancer Conference
Time of Update: 2022-01-22
HK), a clinical-stage biopharmaceutical company with the ability to integrate the whole process of biological drug discovery, research and development, process development and production, announced that the US Phase I clinical trial of TST001 will be held on January 20-22, 2022 Presented as a Trial in Progress (TiP) poster at the American Society of Clinical Oncology Symposium on Gastrointestinal Oncology (ASCO GI) in San Francisco .
-
Shandong pharmaceutical company enters the market, the best-selling antipsychotic drug AstraZeneca welcomes a rival
Time of Update: 2022-01-21
com data, the total sales of quetiapine fumarate tablets in Chinese public medical institutions and Chinese urban physical pharmacies in 2020 will exceed 1.
com data, the total sales of quetiapine fumarate tablets in Chinese public medical institutions and Chinese urban physical pharmacies in 2020 will exceed 1.
-
The first cooperation project between Tianyan Pharmaceutical and Exelixis' original masked safe antibody conjugate drug has successfully reached a key milestone
Time of Update: 2022-01-10
On December 23, 2021, Tianyan Pharmaceuticals announced that the first cooperation project with Exelixis reached at the beginning of the year for a precision masking safe antibody conjugate drug (ADC) developed based on the core technology of Tianyan’s proprietary safe antibody (SAFEbody™) has been completed.
-
CD47 meets PD-L1, mutual achievement and exploration of infinite possibilities!
Time of Update: 2022-01-10
In addition, Maiwei Biologics has also deployed 6MW3411, a bispecific antibody of PD-L1 and NK cell immune checkpoint, which is the first of its kind, and is expected to enter the clinical research phase in 2022 .
-
The critical illness protection rate is 96.0%, the first domestic adenovirus vector new crown vaccine global multi-center phase III clinical data announced
Time of Update: 2022-01-10
HK) recently published a recombinant new coronavirus vaccine (type 5) in the international authoritative medical journal "The Lancet" Adenovirus vector) The final effective rate and interim safety analysis results of the global multi-center phase III clinical trial of Kevisa® .
-
Harbin Sanlian entered the administrative examination and approval stage with the imitation of the 4 types of flurbiprofen gel plaster reported for production
Time of Update: 2022-01-10
Sales of terminal medicinal plasters in physical pharmacies in cities in China (unit: ten thousand yuan) Source: Mi Nei. com, China's urban physical pharmacy terminal competition pattern In recent years, the market scale of terminal medicinal plasters in Chinese urban physical pharmacies has steadily expanded.
